BioCryst Pharmaceuticals Inc. [BCRX] Stock trading around $9.50 per share: What’s Next?



BioCryst Pharmaceuticals Inc. [NASDAQ: BCRX] closed the trading session at $9.50 on 04/26/22. The day’s price range saw the stock hit a low of $9.48, while the highest price level was $10.24. The company report on April 21, 2022 that BioCryst to Report First Quarter 2022 Financial Results on May 5.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2022 financial results Thursday, May 5, 2022.

BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update.

The stocks have a year to date performance of -31.41 percent and weekly performance of -7.05 percent. The stock has been moved at -38.55 percent over the last six months. The stock has performed -40.59 percent around the most recent 30 days and changed -35.15 percent over the most recent 3-months.

If compared to the average trading volume of 4.42M shares, BCRX reached to a volume of 4652599 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about BioCryst Pharmaceuticals Inc. [BCRX]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BCRX shares is $19.18 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BCRX stock is a recommendation set at 2.10. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Barclays have made an estimate for BioCryst Pharmaceuticals Inc. shares, keeping their opinion on the stock as Equal Weight, with their previous recommendation back on April 18, 2022. While these analysts kept the previous recommendation, BofA Securities dropped their target price from $21 to $14. The new note on the price target was released on April 11, 2022, representing the official price target for BioCryst Pharmaceuticals Inc. stock. Previously, the target price had yet another raise to $16, while Oppenheimer analysts kept a Outperform rating on BCRX stock.

The Average True Range (ATR) for BioCryst Pharmaceuticals Inc. is set at 1.03, with the Price to Sales ratio for BCRX stock in the period of the last 12 months amounting to 11.90.

BCRX stock trade performance evaluation

BioCryst Pharmaceuticals Inc. [BCRX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -7.05. With this latest performance, BCRX shares dropped by -40.59% in over the last four-week period, additionally sinking by -38.55% over the last 6 months – not to mention a drop of -22.76% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BCRX stock in for the last two-week period is set at 31.79, with the RSI for the last a single of trading hit 29.15, and the three-weeks RSI is set at 34.50 for BioCryst Pharmaceuticals Inc. [BCRX]. The present Moving Average for the last 50 days of trading for this stock 15.38, while it was recorded at 9.85 for the last single week of trading, and 14.74 for the last 200 days.

BioCryst Pharmaceuticals Inc. [BCRX]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and BioCryst Pharmaceuticals Inc. [BCRX] shares currently have an operating margin of -113.08 and a Gross Margin at +94.88. BioCryst Pharmaceuticals Inc.’s Net Margin is presently recorded at -117.11.

BioCryst Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.30 and a Current Ratio set at 5.50.

Earnings per share (EPS) analysis for BioCryst Pharmaceuticals Inc. [BCRX] stock

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BCRX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for BioCryst Pharmaceuticals Inc. go to 15.20%.

BioCryst Pharmaceuticals Inc. [BCRX]: Insider Ownership positions

There are presently around $1,196 million, or 68.00% of BCRX stock, in the hands of institutional investors. The top three institutional holders of BCRX stocks are: BLACKROCK INC. with ownership of 14,787,395, which is approximately -3.545% of the company’s market cap and around 1.10% of the total institutional ownership; BAKER BROS. ADVISORS LP, holding 12,710,818 shares of the stock with an approximate value of $128.0 million in BCRX stocks shares; and VANGUARD GROUP INC, currently with $94.79 million in BCRX stock with ownership of nearly 0.382% of the company’s market capitalization.

Positions in BioCryst Pharmaceuticals Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 111 institutional holders increased their position in BioCryst Pharmaceuticals Inc. [NASDAQ:BCRX] by around 24,952,062 shares. Additionally, 81 investors decreased positions by around 9,686,167 shares, while 43 investors held positions by with 84,159,775 shares. The mentioned changes placed institutional holdings at 118,798,004 shares, according to the latest SEC report filing. BCRX stock had 36 new institutional investments in for a total of 9,374,888 shares, while 29 institutional investors sold positions of 1,767,258 shares during the same period.